Skip to content

    Breast Cancer Health Center

    Font Size

    Aromatase Inhibitors May Raise Heart Risks

    Newer Breast Cancer Drugs May Carry Higher Risk of Heart Problems Than Tamoxifen: Study
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Dec. 9, 2010 (San Antonio) -- Postmenopausal women with early breast cancer who take newer hormone drugs known as aromatase inhibitors are 26% more likely to develop heart disease than those who take the old standby tamoxifen, researchers report.

    "Treatment with aromatase inhibitors is associated with a significant increase in the risk of cardiovascular events, specifically heart attacks, angina, and heart failure, compared with tamoxifen," says Eitan Amir, MD, a senior fellow in oncology and hematology at the Princess Margaret Hospital in Toronto.

    However, the actual risk of any individual woman developing heart problems was relatively small -- about 4% -- in women taking either aromatase inhibitors or tamoxifen, he says.

    In fact, the analysis showed that 132 patients must be treated with an aromatase inhibitor before one cardiovascular problem occurs. "This number needed to harm is relatively high," Amir says.

    But a woman who already has risk factors for heart disease and takes an aromatase inhibitor has a 7% chance of developing heart problems, Amir tells WebMD.

    For the study, Amir polled the results of seven trials of tamoxifen and aromatase inhibitors involving nearly 30,000 postmenopausal women with early breast cancer.

    The study was presented at the San Antonio Breast Cancer Symposium.

    Aromatase Inhibitors vs. Tamoxifen: How they Work

    About two-thirds of breast tumors are fueled by estrogen.

    Tamoxifen, which blocks estrogen from getting into cancer cells, slowing tumor growth, has been used for decades to treat breast cancer.

    In recent years, its use has been largely supplanted by aromatase inhibitors, which actually shut down the body's ability to make estrogen.

    Aromatase Inhibitors vs. Tamoxifen: What Should Women Do?

    The findings suggest that women at risk for heart disease should limit use of aromatase inhibitors, Amir says.

    "Starting with tamoxifen and then switching to an aromatase inhibitor after several years -- rather than starting with an aromatase inhibitor and staying on it -- may reduce the risk of dying from causes other than breast cancer," he says. "But this is just a hypothesis at this point."

    An expert who worked on the landmark ATAC study that first showed the effectiveness of aromatase inhibitors disagrees.

    Today on WebMD

    Breast Cancer Overview
    From mammograms to living after treatment.
    Dealing with breast cancer
    Get answers to your questions.
    woman having mammogram
    The 3 latest tips to know.
    woman undergoing breast cancer test
    Most abnormalities aren’t breast cancer.
    Resolved To Quit Smoking
    Breast Cancer Treatments Improving
    Woman getting mammogram
    Screening Tests for Women
    serious woman
    Pink badge on woman chest to support breat cancer
    what is your cancer risk
    breast cancer survivors